The development of monoclonal antibody-drug and radionuclide conjugates that target cancer oocyte antigens like SAS1B on the tumor cell surface could create next generation therapeutics that selectively target tumors while limiting side effects on normal healthy tissues. Cancer oocyte antigens may lead to front line therapeutics that dramatically improve the lives of patients in a wide range of cancer indications. Produced by HFP | Media by Eduardo Montes-Bradley

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…